Usefulness of N-terminal pro-brain natriuretic peptide and C-reactive protein to predict ICU mortality in unselected medical ICU patients: A prospective, observational study

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Wang, Feilong ^a   Pan, Wenzhi ^b   Pan, Shuming ^a   Wang, Shuyun ^a   Ge, Qinmin ^a   Ge, Junbo ^b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; BLOOD; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CRITICAL CARE; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79251541749     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10004     Document Type: Article

References (38)

1. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007, 50:2357-2368. 10.1016/j.jacc.2007.09.021, 18154959.
2. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004, 36:505-513. 10.1016/j.yjmcc.2004.01.001, 15081310.
3. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95:948-954. 10.1016/j.amjcard.2004.12.032, 15820160.
4. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007, 115:3103-3110. 10.1161/CIRCULATIONAHA.106.666255, 17548729.
5. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN, . Val-HeFT Investigators Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal pro-BNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1558. 10.1373/clinchem.2006.069575, 16777915, Val-HeFT Investigators.
6. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E, . PEACE Investigators Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 2007, 50:205-214. 10.1016/j.jacc.2007.03.038, 17631211, PEACE Investigators.
7. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, Mannucci PM, Mininni N, Prando MD, Tubaro M, Vernocchi A, Vecchio C, . Italian Working Group on Atherosclerosis Thrombosis and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004, 110:128-134. 10.1161/01.CIR.0000134480.06723.D8, 15197143, Italian Working Group on Atherosclerosis Thrombosis and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO).
8. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663. 10.1056/NEJMoa031994, 14960742.
9. Januzzi JL, Morss A, Tung R, Pino R, Fifer MA, Thompson BT, Lee-Lewandrowski E. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 2006, 10:R37. 10.1186/cc4839, 1550815, 16507171.
10. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, Loundou A, Perrin G, Auffray JP, Portugal H, Papazian L. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005, 33:1001-1007. 10.1097/01.CCM.0000162561.82012.E9, 15891328.
11. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettila V. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007, 35:1277-1283. 10.1097/01.CCM.0000261893.72811.0F, 17414731.
12. Shah KB, Nolan MM, Rao K, Wang DJ, Christenson RH, Shanholtz CB, Mehra MR, Gottlieb SS. The characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients. Am J Med 2007, 120:1071-1077. 10.1016/j.amjmed.2007.07.032, 18060928.
13. Kotanidou A, Karsaliakos P, Tzanela M, Mavrou I, Kopterides P, Papadomichelakis E, Theodorakopoulou M, Botoula E, Tsangaris I, Lignos M, Ikonomidis I, Ilias I, Armaganidis A, Orfanos SE, Dimopoulou I. Prognostic importance of increased plasma amino-terminal pro-brain natriuretic peptide levels in a large noncardiac, general intensive care unit population. Shock 2009, 31:342-347. 10.1097/SHK.0b013e31818635b6, 18791494.
14. Almog Y, Novack V, Megralishvili R, Kobal S, Barski L, King D, Zahger D. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth Analg 2006, 102:1809-1815. 10.1213/01.ane.0000217202.55909.5d, 16717330.
15. Meyer B, Huelsmann M, Wexberg P, Delle Karth G, Berger R, Moertl D, Szekeres T, Pacher R, Heinz G. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007, 35:2268-2273. 10.1097/01.CCM.0000284509.23439.5B, 17717488.
16. Jefic D, Lee JW, Jefic D, Savoy-Moore RT, Rosman HS. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 2005, 128:288-295. 10.1378/chest.128.1.288, 16002948.
17. Christenson RH. What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care?. Clin Chem Lab Med 2008, 46:1524-1532. 10.1515/CCLM.2008.294, 18847367.
18. Ho KM, Lee KY, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. Intensive Care Med 2008, 34:481-487. 10.1007/s00134-007-0928-0, 17992507.
19. Litton E, Ho KM, Chamberlain J, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a nested case-control study. Crit Care Resusc 2007, 9:19-25.
20. Grander W, Dünser M, Stollenwerk B, Siebert U, Dengg C, Koller B, Eller P, Tilg H. C-Reactive Protein Levels and Post-ICU Mortality in Nonsurgical Intensive Care Patients. Chest 2010, 138:856-862. 10.1378/chest.09-1677, 20173056.
21. Schuetz P, Müller B, Nusbaumer C, Wieland M, Christ-Crain M. Circulating levels of GH predict mortality and complement prognostic scores in critically ill medical patients. Eur J Endocrinol 2009, 160:157-163. 10.1530/EJE-08-0786, 19022915.
22. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Mélot C, Vincent JL. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003, 123:2043-2049. 10.1378/chest.123.6.2043, 12796187.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
24. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890. 10.1093/aje/kwh101, 15105181.
25. Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 2008, 149:751-760.
26. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009, 150:795-802. 2782591, 19487714.
27. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
28. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003, 338:107-115. 10.1016/j.cccn.2003.08.016, 14637274.
29. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266. 10.1016/S0272-6386(02)70081-4, 11904577, National Kidney Foundation.
30. Nagelkerke N. A note on a general definition of the coefficient of determination. Biometrika 1991, 78:691-692.
31. Youden WJ. Index for rating diagnostic tests. Cancer 1950, 3:32-35. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3, 15405679.
32. Mackinnon A, Mulligan R. Combining cognitive testing and informant report to increase accuracy in screening for dementia. Am J Psychiatry 1998, 155:1529-1535.
33. Hanley JA, McNeil BJ. A method of comparing the areas under ROC curves derived from same cases. Radiology 1983, 148:839-843.
34. Chua G, Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004, 8:R248-250. 10.1186/cc2889, 522851, 15312225.
35. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, . Breathing Not Properly Multinational Study Investigators B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003, 41:571-579. 10.1053/ajkd.2003.50118, 12612980, Breathing Not Properly Multinational Study Investigators.
36. Harada E, Nakagawa O, Yoshimura M, Harada M, Nakagawa M, Mizuno Y, Shimasaki Y, Nakayama M, Yasue H, Kuwahara K, Saito Y, Nakao K. Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptide in rat cardiocyte culture. J Mol Cell Cardiol 1999, 31:1997-2006. 10.1006/jmcc.1999.1030, 10591026.
37. Rudiger A, Fischler M, Harpes P, Gasser S, Hornemann T, von Eckardstein A, Maggiorini M. In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. Int J Cardiol 2008, 126:28-31. 10.1016/j.ijcard.2007.03.108, 17477984.
38. Ammann P, Fehr T, Minder EI, Günter C, Bertel O. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001, 27:965-969. 10.1007/s001340100920, 11497154.